Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

NCT05455697 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma
Grade 3b Follicular Lymphoma
High Grade B-Cell Lymphoma

Interventions

PROCEDURE: Bone Marrow Biopsy
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Prednisone
BIOLOGICAL: Retifanlimab
BIOLOGICAL: Rituximab and Hyaluronidase Human
BIOLOGICAL: Tafasitamab
DRUG: Vincristine
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Multigated Acquisition Scan
OTHER: Fludeoxyglucose F-18
PROCEDURE: Positron Emission Tomography
PROCEDURE: Computed Tomography
PROCEDURE: Biospecimen Collection
DRUG: Polatuzumab Vedotin

Sponsor

University of Washington